FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600372273> ?p ?o ?g. }

• W2600372273 endingPage "33500" @default.
• W2600372273 startingPage "33487" @default.
• W2600372273 abstract "// Naoko Tsuyama 1 , Daisuke Ennishi 2 , Masahiro Yokoyama 3 , Satoko Baba 4 , Reimi Asaka 1, 4 , Yuko Mishima 3 , Yasuhito Terui 3 , Kiyohiko Hatake 3 and Kengo Takeuchi 1, 4 1 Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan 2 Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 3 Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan 4 Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan Correspondence to: Kengo Takeuchi, email: kentakeuchi-tky@umin.net Keywords: diffuse large B-cell lymphoma, CD5, CD8, aberrant expression, T-cell marker Received: October 20, 2016      Accepted: February 28, 2017      Published: March 23, 2017 ABSTRACT Expression of T-cell markers, generally investigated for immunophenotyping of T-cell lymphomas, is also observed in several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We previously reported that CD5 expression in DLBCL is an inferior prognostic factor in the era of rituximab. However, data regarding the frequencies, histological relevance, and prognostic importance of T-cell markers other than CD5 are currently unavailable. In the present study, we comprehensively evaluated the expression of T-cell markers (CD2, CD3, CD4, CD5, CD7, and CD8) in 501 B-cell lymphomas, including 225 DLBCLs, by flow cytometry and subsequent immunohistochemistry. T-cell markers other than CD5, such as CD2, CD4, CD7, and CD8, were expressed in 27 (5%) patients, and notably, all of these cases were classified as large B-cell lymphoma subtypes: 25 DLBCLs and 2 intravascular large B-cell lymphomas. CD5 and other T-cell markers were expressed in 15% (31/225) and 10% (25/225) of DLBCL cases, respectively. Five of them co-expressed CD5 and other T-cell markers. Retrospectively analyzing the prognostic relevance of T-cell markers in 169 patients with primary DLBCL treated with rituximab-based chemotherapy, we showed that only CD5 was a strong predictor of poor survival. This study provides information about the occurrence of T-cell markers other than CD5 in B-cell lymphomas, their frequent histological subtypes, and their prognostic significance in DLBCL. CD5 was reconfirmed as a negative prognostic marker in DLBCL patients receiving rituximab-inclusive chemotherapy, whereas T-cell markers other than CD5 were found to have no impact on clinicopathological and survival analyses." @default.
• W2600372273 created "2017-04-07" @default.
• W2600372273 creator A5002620851 @default.
• W2600372273 creator A5010120453 @default.
• W2600372273 creator A5024418836 @default.
• W2600372273 creator A5031782171 @default.
• W2600372273 creator A5038191750 @default.
• W2600372273 creator A5044544485 @default.
• W2600372273 creator A5047640708 @default.
• W2600372273 creator A5048998794 @default.
• W2600372273 creator A5061361157 @default.
• W2600372273 date "2017-03-23" @default.
• W2600372273 modified "2023-10-10" @default.
• W2600372273 title "Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of<i>de novo</i>diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas" @default.
• W2600372273 cites W1579193869 @default.
• W2600372273 cites W1907582144 @default.
• W2600372273 cites W1945492357 @default.
• W2600372273 cites W1974712554 @default.
• W2600372273 cites W1985179260 @default.
• W2600372273 cites W1990946912 @default.
• W2600372273 cites W1992539583 @default.
• W2600372273 cites W2005803139 @default.
• W2600372273 cites W2007018042 @default.
• W2600372273 cites W2012648627 @default.
• W2600372273 cites W2012989961 @default.
• W2600372273 cites W2028192419 @default.
• W2600372273 cites W2028920820 @default.
• W2600372273 cites W2030581846 @default.
• W2600372273 cites W2041206629 @default.
• W2600372273 cites W2052621866 @default.
• W2600372273 cites W2065496272 @default.
• W2600372273 cites W2069880909 @default.
• W2600372273 cites W2080391969 @default.
• W2600372273 cites W2086587682 @default.
• W2600372273 cites W2088756112 @default.
• W2600372273 cites W2100306945 @default.
• W2600372273 cites W2101756810 @default.
• W2600372273 cites W2111457520 @default.
• W2600372273 cites W2111755272 @default.
• W2600372273 cites W2131934389 @default.
• W2600372273 cites W2133201432 @default.
• W2600372273 cites W2133289462 @default.
• W2600372273 cites W2134958656 @default.
• W2600372273 cites W2137705935 @default.
• W2600372273 cites W2139987022 @default.
• W2600372273 cites W2140137149 @default.
• W2600372273 cites W2144417729 @default.
• W2600372273 cites W2158267770 @default.
• W2600372273 cites W2168228430 @default.
• W2600372273 cites W2171033786 @default.
• W2600372273 cites W2320891899 @default.
• W2600372273 cites W2327336874 @default.
• W2600372273 cites W2328347289 @default.
• W2600372273 cites W2335104805 @default.
• W2600372273 cites W2426045282 @default.
• W2600372273 cites W3138826133 @default.
• W2600372273 doi "https://doi.org/10.18632/oncotarget.16532" @default.
• W2600372273 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5464884" @default.
• W2600372273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28380441" @default.
• W2600372273 hasPublicationYear "2017" @default.
• W2600372273 type Work @default.
• W2600372273 sameAs 2600372273 @default.
• W2600372273 citedByCount "22" @default.
• W2600372273 countsByYear W26003722732017 @default.
• W2600372273 countsByYear W26003722732018 @default.
• W2600372273 countsByYear W26003722732019 @default.
• W2600372273 countsByYear W26003722732020 @default.
• W2600372273 countsByYear W26003722732021 @default.
• W2600372273 countsByYear W26003722732022 @default.
• W2600372273 countsByYear W26003722732023 @default.
• W2600372273 crossrefType "journal-article" @default.
• W2600372273 hasAuthorship W2600372273A5002620851 @default.
• W2600372273 hasAuthorship W2600372273A5010120453 @default.
• W2600372273 hasAuthorship W2600372273A5024418836 @default.
• W2600372273 hasAuthorship W2600372273A5031782171 @default.
• W2600372273 hasAuthorship W2600372273A5038191750 @default.
• W2600372273 hasAuthorship W2600372273A5044544485 @default.
• W2600372273 hasAuthorship W2600372273A5047640708 @default.
• W2600372273 hasAuthorship W2600372273A5048998794 @default.
• W2600372273 hasAuthorship W2600372273A5061361157 @default.
• W2600372273 hasBestOaLocation W26003722731 @default.
• W2600372273 hasConcept C113067387 @default.
• W2600372273 hasConcept C121608353 @default.
• W2600372273 hasConcept C126322002 @default.
• W2600372273 hasConcept C142724271 @default.
• W2600372273 hasConcept C143998085 @default.
• W2600372273 hasConcept C194409129 @default.
• W2600372273 hasConcept C196166836 @default.
• W2600372273 hasConcept C203014093 @default.
• W2600372273 hasConcept C2778559949 @default.
• W2600372273 hasConcept C2779338263 @default.
• W2600372273 hasConcept C502942594 @default.
• W2600372273 hasConcept C553184892 @default.
• W2600372273 hasConcept C71924100 @default.
• W2600372273 hasConceptScore W2600372273C113067387 @default.
• W2600372273 hasConceptScore W2600372273C121608353 @default.
• W2600372273 hasConceptScore W2600372273C126322002 @default.
• W2600372273 hasConceptScore W2600372273C142724271 @default.

• next